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Abstract
Background: The formation of blood vessels within solid tumors directly contributes to cancer growth and
metastasis. Until recently, tumor vasculature was thought to occur exclusively via endothelial cell (EC) lined
structures (i.e. angiogenesis), but a second source of tumor vasculature arises from the cancer cells themselves, a
process known as vasculogenic mimicry (VM). While it is generally understood that the function of VM vessels is the
same as that of EC-lined vessels (i.e. to supply oxygen and nutrients to the proliferating cancer cells), the molecular
mechanisms underpinning VM are yet to be fully elucidated.
Methods: Human VM-competent melanoma cell lines were examined for their VM potential using the in vitro
angiogenesis assays (Matrigel), together with inhibition studies using small interfering RNA and blocking
monoclonal antibodies. Invasion assays and adhesion assays were used to examine cancer cell function.
Results: Herein we demonstrate that CD36, a cell surface glycoprotein known to promote angiogenesis by ECs,
also supports VM formation by human melanoma cancer cells. In silico analysis of CD36 expression within the
melanoma cohort of The Cancer Genome Atlas suggests that melanoma patients with high expression of CD36
have a poorer clinical outcome. Using in vitro ‘angiogenesis’ assays and CD36-knockdown approaches, we reveal
that CD36 supports VM formation by human melanoma cells as well as adhesion to, and invasion through, a cancer
derived extracellular matrix substrate. Interestingly, thrombospondin-1 (TSP-1), a ligand for CD36 on ECs that inhibits
angiogenesis, has no effect on VM formation. Further investigation revealed a role for laminin, but not collagen or
fibronectin, as ligands for CD36 expressing melanoma cells.
Conclusions: Taken together, this study suggests that CD36 is a novel regulator of VM by melanoma cancer cells
that is facilitated, at least in part, via integrin-α3 and laminin. Unlike angiogenesis, VM is not perturbed by the
presence of TSP-1, thus providing new information on differences between these two processes of tumor
vascularization which may be exploited to combat cancer progression.
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Background
Angiogenesis is the most common mechanism by which
tumors become vascularized and metastasize. However,
the growing mass can also utilise other processes to
form vascular networks, such as vasculogenic mimicry
(VM). First identified in aggressive uveal melanoma cells,
VM has since been seen in several aggressive malignan-
cies such as glioblastoma [1–3], colorectal cancer [4, 5],
breast cancer [6, 7], ovarian cancer [8, 9], pancreatic
cancer [10] and prostate cancer [11]. VM occurs when
highly aggressive malignant cells undergo cellular
phenotypic changes to resemble endothelial cells (ECs)
which form the inner lining of all vasculature. While
these malignant cells display EC markers, i.e. vascular
endothelial (VE)-cadherin, ephrin receptor A2 (EphA2)
and E-selectin, and like ECs can secrete many basement
membrane relevant proteins, they do however have little
to no expression of EC-specific proteins such as CD31
(PECAM-1) and TIE-2 [12, 13]. Histological staining
with the periodic acid-Schiff stain (PAS, recognizing
basement membrane proteins) used in conjunction with
an antibody to CD31 is the universally accepted protocol
to distinguish VM structures as PAS-positive/CD31-
negative from the EC-lined PAS-positive/CD31-positive
vasculature [14–16].
The aggressive nature of VM is supported by evidence
of these structures anastomosing with traditional EC-
lined tumor vasculature [17]; and in doing so, it further
enables the solid tumor mass to gain access to oxygen
and nutrients for growth [18]. VM content in tumors is
undeniably an indicator of poor patient prognosis, in-
cluding metastatic disease and overall survival [16, 19].
Meta-analyses of different cancer types show that pa-
tients with tumors that are high in VM content have a
significantly lower 5-year overall survival rate when
compared to those with little/no VM content [20]. Des-
pite the similarities between angiogenesis and VM,
current anti-angiogenic approaches fail to target VM
vascular structures and indeed the use of antiangiogenic
therapy (bevacizumab) has been shown to increase VM
in ovarian and breast cancer [21, 22]. Anti-VM therapies
have had limited success, with currently only one drug,
CVM-1118 (NCT03582618), in Phase 2 open label clin-
ical trial [23, 24]. Hence, understanding the mechanisms
involved in VM formation is clearly clinically important.
CD36 is an 88 kDa cell surface glycoprotein well docu-
mented as a scavenger receptor on many cell types, in-
cluding platelets, phagocytic cells, adipocytes,
erythrocytes, specialized epithelia, myocytes and micro-
vascular endothelium (reviewed in [25]). The functional
diversity of CD36 is underpinned by its binding to dis-
tinct ligands including long chain fatty acids, phospho-
lipids, oxidized low-density lipoprotein (oxLDL),
amyloid proteins, advanced glycation end products and
thrombospondin (TSP) [25]. In tumor tissues, CD36 is
expressed by cancer cells, ECs, stromal cells and im-
mune cells [26] with numerous studies supporting the
notion that CD36 participates in the progression of can-
cer [27–29]. More specifically, retrospective analyses
suggest that elevated levels of CD36 correlate with poor
prognosis in patients with glioma, cervical cancer, ovar-
ian cancer, lung cancer, squamous-cell carcinoma, blad-
der cancer, and luminal A breast cancer [27–30].
Consistent with this, overexpression studies have shown
CD36 to increase the migration and invasion of cervical
cancer cells in vitro, and its knockdown inhibited their
metastatic potential [30]. Pascual and colleagues further
demonstrated that short hairpin RNA-mediated deple-
tion of CD36 significantly reduced metastases in models
of melanoma (501mel) and breast cancer (MCF-7)
in vivo [29]. Hypoxia is a well-known initiator of tumor
vascularization and hypoxia has also been documented
to elevate CD36 expression on microvascular ECs
(MVECs) [31]. Taken together, these findings begin to
reveal an important inter-relationship between cancer
cells, tumor ECs and CD36. Interestingly, the CD36 lig-
and TSP-1 has been identified as a potent inhibitor of
angiogenesis as it renders ECs non-responsive to pro-
angiogenic stimuli such as vascular endothelial growth
factor (VEGF) via changes in intracellular signaling path-
ways [32, 33] and its promotion of apoptosis [34]. Ele-
vated levels of TSP-1 have indicated some suppressive
control of tumor growth and cancer metastasis [35],
likely via inhibition of tumor vasculature.
On the whole, the expression of CD36 has poor impli-
cations in cancer, and while CD36 has gained significant
attention in recent years, its role in tumor vasculature
and cancer progression is still not fully understood. The
aim of the present study is to investigate the currently
unknown role of CD36 in VM by melanoma cells.
Methods
Bioinformatics analysis of publicly available datasets
To analyze The Cancer Genome Atlas (TCGA) data,
RNA sequencing (RNA-seqV2) and clinical (Biotab) data
were downloaded from the Data Portal at http://
cancergenome.nih.gov/. Data were analyzed in Biocon-
ductor, using the edgeR package to perform differential
gene expression analysis. A Kaplan Meier plot was gen-
erated to compare the overall survival between patients
expressing the top 10% of CD36 against the patients ex-
pressing the bottom 10% of CD36.
Cell culture
Human melanoma cell lines C32 and SK-MEL-28 were
gifted from G McArthur (Peter MacCallum Cancer
Centre, Melbourne, Vic, AUS) and cultured in RPMI
1640 (Gibco by Life Technologies, California, USA)
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containing 10% fetal bovine serum (FBS) (Hyclone, GE
Healthcare Sciences, Utah, USA) and 1% Glutamax 1x
(Gibco) and cultured under standard conditions (37 °C,
5% CO2). The isolation of endothelial colony-forming
cells (ECFCs) from healthy human peripheral blood, as
previously described [36], was approved by the human
ethics committees of the University of South Australia
(UniSA HREC #201187). Briefly, collagen I-coated plates
were seeded with lymphoprep enriched mononuclear
cells and cultured in EGM-2 media (Lonza) containing
20% Embryonic Stem cell screened fetal bovine serum
(Hyclone, GE Healthcare, Chicago, IL, USA) until colony
formation at ~ 14 days culture after which time the cells
were passaged and cultured for no more than 9 passages.
Human lung microvascular endothelial cells (HMVEC)
were purchased from the Lonza (Basel, Switzerland) and
cultured in Lonza EBM-2 basal medium to low passage
number.
Flow cytometry
To determine cell surface expression of CD36, cells were
labelled with anti-human CD36 antibody (FA6–152,
Stem Cell Technologies, Vancouver, Canada) or isotype
control (IgG1 κ) at a concentration of 10 μg/ml in
RPMI1640 media (Sigma-Aldrich, Merck, Sydney
Australia) containing 10% FBS. Cells were then washed
and stained with a secondary antibody, goat anti-mouse
IgG H&L Dylight 650 (Clone ab96882, Abcam, Cam-
bridge, United Kingdom) at a concentration of 5 μg/ml.
Similarly, cells were labelled with directly conjugated
antibodies within panels containing one or more of the
following; anti-CD144 (VE-cadherin)-FITC, anti-
CD31(PECAM)-PE, anti-Tie-2-Alexa Fluor 647, anti-
CD146 (MCAM)-PE (all BD Bioscience) and anti-CD309
(VEGFR2)-Alexa Fluor 647 (Biolegend), with non-
specific isotype control antibodies, IgG1-FITC, IgG1-PE
and IgG1-Alexa Fluor 647 (all BD Bioscience). Cell via-
bility was determined via 7AAD (BD Biosciences) stain-
ing at a 1:20 dilution. Samples were processed using a
BD Accuri C6 flow cytometer (BD, Becton, Dickinson
and Company, New Jersey, USA) and data analyzed
using FCS Express 4 Flow Research Edition (De Novo
software, Los Angeles, USA).
CD36 knockdown using siRNA
CD36 targeting small interfering RNAs (siRNAs)
Trilencer-27 Human siRNA duplexes at 20 μM were
purchased (Origene, Maryland, USA) with three CD36
targeting siRNAs (duplex sequences: SR319610A rCrAr-
ArCrCrUrArUrUrGrGrUrCrArArGrCrCrArUrCrArGAA,
SR319610B rGrGrCrCrUrGrArUrArGrArArArUrGrArUr
CrUrUrArCrUCA and SR319610C rGrGrArUrUrArArAr
CrCrCrArArArUrGrArArGrArArGrAAC) plus a non-
targeting scrambled (SCR) siRNA used as a negative
control. Transfection was performed using Lipofectamine
RNAiMAX (Invitrogen by Life Technologies, California,
USA) as per the manufacturer’s instructions with the
knockdown maximized at 5 nM and validated by flow
cytometry.
Vasculogenic mimicry (VM) assays
VM assays were performed on Geltrex LDEV-Free Re-
duced Growth Factor Basement Membrane Matrix (Life
Technologies, California, USA) with 10 μl coating each
of a 15 well μ-Angiogenesis culture slides (Ibidi, Mar-
tinsreid, Germany) and allowed to solidify over 30 min
at 37 °C. Human melanoma cancer cells were then
seeded at 2 × 104 cells/well for C32 cells and 5 × 103
cells/well for SK-MEL-28 cells and after 6 h incubation
at 37 °C, images of each well were obtained using the
EVOS XL Core Imaging System (Thermo Fisher Scien-
tific) with brightness of the images adjusted equally
across groups to enhance image contrast for ease of
readers. VM structures were defined as multi-cellular ar-
rangements forming vessel-like structures from one
branch point to another [16] and VM in each well was
counted in blinded manner. A minimum of three inde-
pendent experiments were performed. Similar experi-
ments included cells without or with CD36-targeting
siRNA knockdown or those pre-treated with TSP-1 (150
or 1500 ng/ml), an anti-CD36 blocking antibody (10 μg/
ml, FA6–152) or an isotype control (IgG1) for 30 min at
4 °C prior to seeding.
Angiogenesis assays
Human lung microvascular endothelial cells (HMVEC)
were serum starved overnight in EBM-2 basal medium
(Lonza, Basel, Switzerland) at 37 °C prior to seeding onto
Geltrex at a concentration of 2 × 104 cells/well within a
15 well μ-Angiogenesis slide with or without the
addition of TSP-1 (1500 ng/ml) in EBM-2 basal medium
containing EGM-2 MV SingleQuot Kit supplements and
growth factors (Lonza, Basel, Switzerland). After 6 h, im-
ages of the angiogenesis formation were obtained using
the EVOS XL Cell Imaging System. Angiogenesis forma-
tion was determined by blindly counting the vessel-like
structures formed within each well with the use of Ima-
geJ software.
MTS survival assay
HMVEC were seeded into 96-well flat bottom plates at a con-
centration of 2 × 104 cells/well in EBM-2 basal medium con-
taining EGM-2 MV SingleQuot Kit supplements and growth
factors. Cells were incubated at 37 °C for 5 h, washed in 1x
PBS, serum starved in EBM-2 basal medium overnight at
37 °C and then treated without or with TSP-1 (1500 ng/ml)
for 6 h and 24 h at 37 °C. MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium;
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Life Technologies, California, USA) was then added to each
well at a concentration of 0.5mg/ml for 2 h at 37 °C. Viable
cell density was determined by measuring absorbance at 490
nm on the Epoch microplate spectrophotometer (Biotek,
USA).
Inverse invasion assays
Using previously described methods [37], growth factor-
reduced Matrigel diluted 1:1 in cold PBS was loaded into
Transwells (Corning Inc., NY, USA) to set prior to being
inverted and C32 cells (2 × 105/ml ± CD36 knockdown
via siRNA) were seeded onto the underside of the mem-
brane. After four hours, the unbound cells were washed
away and Transwells immersed right-way up in serum-
free HUVEC media ±10% FBS to the upper chamber
and cells allowed to migrate upward into the Matrigel
for two days. Transwells were fixed with paraformalde-
hyde for 30 min, washed with PBS, RNAse-treated
(100 μg/ml, Thermo Fisher) for 30 min, washed with
PBS, and stained with propidium iodide (0.05 mg/ml,
Thermo Fisher). Starting at the membrane, Transwells
were imaged at 10 μm fixed intervals in a direction to-
wards the chemoattractant using Zeiss LSM 700 con-
focal microscope with a 20x objective and z-stack setting
(Carl Zeiss AG, Oberkochen, Germany). From three
fields of view per slice, images were quantified using
ImageJ software, through threshold adjustment and
counting particles (cells), these were then averaged.
Adhesion assays
C32 melanoma cells (1.5 × 104 cells) were seeded into
wells of a flat bottom 96-well plate preloaded overnight
at 4 °C with 10–50 μg/ml collagen I (Becton, Dickinson
and Company, New Jersey, USA), collagen IV (Sigma-Al-
drich, Missouri, United States), laminin (Roche, Basel,
Switzerland), fibronectin (Roche, Basel, Switzerland) or
Geltrex. Cells that had undergone a 72-h CD36-
targeting siRNA knockdown were harvested and resus-
pended in 1 mg/ml of bovine serum albumin (BSA)
(Sigma Aldrich, Missouri, USA) in RPMI 1640 and
seeded into the extracellular matrix (ECM) component
containing wells and incubated at 37 °C for 90 min. Rose
Bengal (Sigma Aldrich, Missouri, USA) diluted in warm
1x PBS to a concentration of 0.05%, was then added to
the cells for 10 min at RT prior to several washes with
PBS. A 1:1 solution of methanol and PBS was then
added to the cells for 10 min prior to the absorbance
reading via spectrophotometry at 562 nm FLUOstar
Omega plate reader (BMG LABTECH GmbH, Offenberg
Germany).
Functional blocking studies using the mouse anti-
integrin-α3 mAb (Clone P1B5; Sigma Aldrich, Missouri,
USA) were performed by pre-incubating C32 melanoma
cells at 37 °C with anti-integrin-α3 mAb at 50 μg/mL for
30 min prior to cell attachment to wells coated with hu-
man laminin at 50 μg/ml as described above. Images of
each well were obtained using the EVOS XL Core Im-
aging System.
Immunocytochemistry
Circular glass coverslips (Menzel Glaser, Germany) were
placed into a 24-well plate (Nunc) and coated overnight
at 4 °C with EHS-derived mouse laminin (Roche) at
20 μg/mL in PBS. C32 melanoma cells were harvested
and resuspended in RPMI 1640 medium containing BSA
at 1 mg/mL; cells (5 × 104 per well) were allowed to ad-
here and spread for 60 min at 37 °C, and nonadherent
cells removed by gentle washing. Cells were then fixed
with 4% paraformaldehyde/PBS for 10 min at room
temperature. After washing with PBS, cells were perme-
ated with 0.25% Triton X-100 (Sigma-Aldrich) in PBS
for 10 min. Non-specific binding sites were blocked for
90 min using 3% BSA in PBS containing a 1:10 dilution
of nonimmune goat serum. Cells were incubated over-
night at 4 °C with the primary antibodies [mouse anti-
human integrin-α3 at 1 μg/mL (clone P1B5, Merck
Australia); rabbit anti-human paxillin at 0.5 μg/mL (sc-
5574, Santa Cruz Biotechnology), mouse IgG1 isotype
control at 1 μg/mL (BD Bioscience); and purified rabbit
IgG at 0.5 μg/mL (Sigma-Aldrich)] in PBS containing
BSA at 1 mg/mL and then counterstained with a 1:1000
dilution of Alexa Fluor 488–conjugated goat anti-rabbit
and Alexa Fluor 555–conjugated goat anti-mouse IgG
(Life Technologies) as well as a 1:3000 dilution of DAPI
nuclear stain (Sigma-Aldrich) in PBS containing 1 mg/
mL BSA. Coverslips were mounted onto glass slides
using Fluoromount (Sigma-Aldrich), and images were
captured using a 63x objective fluorescence confocal
photomicroscope (LSM800, Carl Zeiss Microscopy, Jena,
Germany).
Statistical analysis
GraphPad PRISM software (San Diego, CA, USA) was
used to perform statistical analyses and significance via a
Mann Whitney U test or one-way ANOVA. In all com-
parisons, p < 0.05 was considered statistically significant.
Results
High CD36 gene expression suggests poor clinical
outcome for patients with melanoma
Data obtained from The Cancer Genome Atlas (TCGA)
was used to determine the significance of CD36 gene ex-
pression in the survival of patients with melanoma
(TCGA-SKCM project, n = 470). Patient data was cate-
gorized into samples within the top 10% of CD36 gene
expression (CD36-high, n = 47) and those within the
bottom 10% of CD36 gene expression (CD36-low, n =
47) (Fig. 1A). Analysis of these two cohorts showed a
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clear trend of decreased overall survival in patients who
have high CD36 gene expression, compared to those
with low CD36 expression, although this difference was
not statistically significant (Fig. 1B).
Melanoma cells perform vasculogenic mimicry which is,
in part, mediated by CD36
To determine whether CD36 expression contributes to
VM in melanoma, in vitro VM assays were performed
using two human melanoma cells lines, C32 and SK-
MEL-28 without and with CD36 knockdown. Figure 2A
and E confirm the VM capability of both C32 and SK-
MEL-28 cell lines in vitro with Fig. 2B and F demon-
strating the ability of three different CD36-targeting
siRNA constructs to consistently knockdown CD36 pro-
tein expression with an efficacy of up to 90%. Having
first confirmed that knockdown of CD36 did not com-
promise the viability of the cells (Fig. 2C and G), we
went on to examine the contribution of CD36 to VM
formation. After 72 h of CD36 knockdown, VM forma-
tion was significantly decreased in both the C32 (Fig. 2D
and E) and SK-MEL-28 (Fig. 2H and I) cell lines, result-
ing in fragmented networks.
To elaborate on the potential vascular profile of the
C32 and SK-Mel-28 melanoma cells, flow cytometric
analysis was used to determine the expression of endo-
thelial cell (EC) surface antigens VE-cadherin (CD144),
PECAM (CD31), VEGFR2 (CD309), Tie-2 (CD202b) and
MCAM (CD146). Figure 3 shows the surface expression
of VE-cadherin on ECs but not on either of the melan-
oma cell lines. Interestingly, surface expression of PECA
M was identifiable on ECs and SK-Mel-28 cells, but not
the C32 cells; while VEGFR2, Tie-2 and MCAM were
identified on all three cell types.
Exogenous TSP-1 does not inhibit VM capacity of
melanoma cells
To investigate whether TSP-1, a known inhibitor of angio-
genesis [32, 33] and a well-documented ligand for CD36,
could also interfere with VM formation by CD36-
expressing melanoma cells. In vitro, we performed VM as-
says with the C32 melanoma cells in the presence of in-
creasing concentrations of TSP-1. Based on the literature
of circulating TSP-1 in patient plasma ranging from 245
ng/ml, in healthy individuals, to 3650 ng/ml, in cancer pa-
tients [38], we included 0, 150 and 1500 ng/ml of TSP-1
into the VM assays. Figure 4A illustrates that the VM
structures were not perturbed by the increasing concentra-
tions of TSP-1. Further support for TSP-1 not being the
relevant ligand for CD36 in VM comes from our inclusion
of the anti-CD36 blocking antibody (FA6–152) that specif-
ically blocks CD36 binding to TSP-1 and collagen [39–41].
Figure 4B shows that addition of this anti-CD36 blocking
antibody (10 μg/ml) did not inhibit VM formation, thus
suggesting that neither TSP-1 nor CD36-engaged collagen
are involved in VM formation by melanoma cancer cells.
Importantly, to confirm that our TSP-1 was indeed
functional, we used the CD36 expressing human micro-
vascular endothelial cells (HMVECs, Fig. 4C) in an
angiogenesis assay [32, 33]. First, we confirmed that ex-
posure of 1500 ng/ml of TSP-1 for up to 24 h did not
compromise cell viability (Fig. 4C), prior to addition of
TSP-1 into the angiogenesis assay which showed a sig-
nificant reduction in angiogenesis by the HMVECs when
TSP-1 was present (Fig. 4D). This differential between
EC angiogenesis and cancer cell VM has not been re-
ported previously and goes some way to describing the
important differences between these two-contributing
process of tumor vascularization.
Fig. 1 Association of clinical outcome in melanoma patients with high CD36 expression. (A) Patient data accessed from the TCGA-SKCM project
(n = 470) was categorized into the top and bottom 10% of CD36 gene expression (CD36-high (red) and CD36-low (black), respectively), ****p <
0.0001, unpaired t-test. (B) From the data in A, a Kaplan-Meier analysis was conducted between the CD36-high and CD36-low populations (n = 47
per group)
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Fig. 2 (See legend on next page.)
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Fig. 3 Surface expression profiling of ECs, C32 and SK-Mel-28 cells. The histograms show one representative experiment from n ≥ 3 replicates for
each of the cell types with the dotted lines identifying isotype control stained cells and the solid lines representing cells stained for VE-cadherin,
PECAM, VEGFR2, Tie-2 or MCAM
(See figure on previous page.)
Fig. 2 CD36 inhibition by siRNA attenuates VM by melanoma cells in vitro. (A, E) Representative images of C32 and SK-Mel-28 human melanoma cells
undergoing VM. For each cell line, the left image depicts VM with low magnification (scale bar = 500 μm) and the right image is a zoomed in view of
the same well using higher magnification (scale bar = 100 μm). (B, F) Left panels, flow cytometric histograms of CD36 expression on C32 and SK-Mel-
28 cells with isotype control (dotted line), CD36 (solid black line), and siCD36 knockdown cells (A, blue line; B, red line and C, green line). Right panels,
bar graphs of flow data quantified from experimental repeats, siCD36 (constructs A-C) normalized to scrambled siRNA (siSCR) controls. Data are
expressed as mean ± SEM from n = 3 experiments.***p < 0.001 vs siSCR control, one-way ANOVA. (C, G) Cell viability without and with CD36
knockdown. Data are expressed as mean ± SEM from n = 3 experiments. (D, H) Top panels are representative images of C32 and SK-Mel-28 melanoma
cells undergoing VM without or with siCD36 knockdown. For each cell line, the left image depicts VM with low magnification (scale bar = 500 μm) and
the right image is a zoomed in view of the same well using higher magnification (scale bar = 100 μm). Lower panels illustrate the VM formation
following CD36 knockdown for constructs RNAi A-C. (scale bar = 100 μm) (E, I) Quantitation of VM formation by the cancer cells, normalized to si-SCR
control within each experiment. Data are expressed as mean ± SEM from n = 3 experiments. ***p < 0.001 vs si-SCR control, one-way ANOVA
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CD36 receptor mediates melanoma cell adhesion to
extracellular matrix components
To further investigate the role of CD36 on VM-
competent melanoma cells, we performed inverse in-
vasion assays wherein we tested the ability of C32
melanoma cells (without or with CD36) to crawl
through an extracellular matrix (Matrigel) towards a
chemoattractant (10% FBS). Figure 5A shows that
over 48 h, the cells travelled between 50 and 150 μm
from the Transwell membrane with the majority
Fig. 4 Blocking CD36:TSP-1 interactions does not inhibit VM by melanoma cells. (A) VM formation by C32 melanoma cells assessed following
treatment with 150 and 1500 ng/ml TSP-1. Microscopy images are representative of VM with TSP-1 treatments (scale bar = 100 μm). Right bar
graph, number of VM normalized to untreated (UNT) controls. Data are mean ± SEM from n = 3 experiments. (B) VM formation by C32 melanoma
cells assessed following administration of anti-CD36 mAb (10 μg/ml) or isotype IgG1 control (10 μg/ml) prior to cell seeding for VM assay.
Microscopy images are representative of VM (scale bar = 100 μm). Right bar graph, number of VM normalized to untreated (UNT) controls. Data
are mean ± SEM from n = 3 experiments. (C) Left histogram, flow cytometric analysis of CD36 expression on HMVEC cells with isotype control
(dotted line) and CD36 (solid line). Right bar graph, survival of HMVECs assessed without or with 1500 ng/ml TSP-1 for 6 h. Data are mean ± SEM
from n = 3 experiments. (D) HMVEC angiogenesis without and with 1500 ng/ml TSP-1. Microscopy images are representative of EC angiogenesis
(scale bar = 500 μm). Right bar graph is number of EC branches per well normalized to untreated (UNT) controls. Data are mean ± SEM from n = 3
experiments. *p < 0.05, t-test
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travelling 100 μm over that time. The loss of CD36
(via siRNA knockdown) did not impact on the can-
cer cells being able to invade up to 150 μm. How-
ever, we observed that loss of CD36 significantly
inhibited the number of C32 cells that migrated to-
wards the FBS (Fig. 5A). This difference is best ex-
emplified in Fig. 5B which illustrates the number of
cancer cells at precisely 100 μm from the Transwell
membrane start point. With CD36 knockdown, there
is a 50% reduction in cancer cells at this position.
This data implies that CD36 facilitates an interaction
between cancer cells and the extracellular matrix,
and from our results above, CD36 is unlikely to
interact with TSP-1 or collagen.
Melanoma cells utilize CD36 to bind to laminin substrata
To further investigate how CD36 may be contributing to
cancer cell invasion through the extracellular matrix
components, adhesion assays were performed on Geltrex
and a selection of components contained within Geltrex
known to be bound by CD36, i.e. collagen I, collagen IV
and laminin. Adhesion to fibronectin was also examined
as a matrix component that does not engage CD36.
Figure 6 shows that following knockdown of CD36, the
C32 melanoma cells demonstrated reduced binding to
Geltrex; adding further support to our findings of
reduced VM and invasion. While no changes in cell ad-
hesion were observed for C32 cells exposed to collagen
I, collagen IV or fibronectin, when CD36 was knocked
down, reduced adhesion to laminin was observed for
both CD36-targeting siRNA constructs (Fig. 6).
Binding of melanoma cells to laminin is facilitated
through integrin-α3
Given that Thorne et al previously demonstrated an
association between CD36 and integrin-α3β1 on mel-
anoma cells [42], and that integrin-α3, but not CD36,
binds laminin, we next examined whether blocking
integrin-α3 might inhibit the adhesion of VM-
competent melanoma cells and laminin in vitro. First,
flow cytometry confirmed the cell surface expression
of integrin-α3 on the C32 melanoma cells (Fig. 7A).
In support for integrin-α3 actively engaging with lam-
inin, C32 cells were seeded on to laminin and im-
munocytochemistry identified active focal contacts at
the cell periphery which contained both integrin-α3
and paxillin (Fig. 7B). Finally, we observed that C32
cell adhesion to laminin could be partly blocked via
an anti-integrin-α3 blocking antibody (Fig. 7C).
Fig. 5 CD36 facilitates the migration of melanoma cells. (A) Left panel, quantitated data of the distance travelled by C32 melanoma cells towards
10% FBS with siCD36 (siRNA A or C) or siRNA control (Scrambled). Right panel, quantitated data of total number of invading cells normalized to
control (si-SCR). Data are mean ± SEM from n = 3 experiments. ****p < 0.0001 vs si-SCR, one-way ANOVA. (B) Left confocal images are
representatives taken at a distance of 100 μm from the Transwell membrane start point for si-SCR control or siCD36 (A and C). Images were
captured via a 20x objective on a Zeiss LSM 700 confocal microscope. Right panel, quantitated data of the number of cells at 100 μm from the
Transwell membrane start point. Data are mean ± SEM from n = 3 experiments. ** p < 0.01 vs si-SCR, one-way ANOVA
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Discussion
CD36, most widely known for its role as a scavenger re-
ceptor involved in the uptake of fatty acids, is gaining
interest in the field of cancer research [29, 43, 44]. Ex-
pression of CD36 has been shown to correlate with poor
prognosis (disease-free survival and overall survival) in
luminal A breast cancer, lung squamous cell carcinoma,
bladder cancer and melanoma [29, 45], with studies pri-
marily focusing on the role of CD36 as a receptor for ox-
idized low density lipoprotein (oxLDL). Our own
interrogation of the TCGA-SKCM database suggests
that high expression of CD36 correlates with poor clin-
ical outcome for patients with melanoma (albeit not sig-
nificantly) and corroborates the study by Nath and Chan
[45]; thus lending further weight to investigating CD36
in melanoma.
Here we reveal an unexpected role for CD36 in VM
formation by melanoma cancer cells. More specifically,
using the in vitro angiogenesis assay with two human
melanoma VM-competent cell lines [16], we observed
that knockdown of CD36 by siRNA significantly per-
turbed VM formation. To further examine the contribu-
tion of CD36 to VM formation, our invasion assays
showed that in the absence of CD36 on melanoma can-
cer cells, their ability to migrate through an ECM was
compromised, thus suggesting a direct interaction of
CD36 with one or more components of the ECM. Inter-
estingly, TSP-1, a known ligand of CD36 that inhibits
angiogenesis by ECs [32, 46], was unable to inhibit VM
formation by the cancer cells. Congruent with this, a
CD36 blocking antibody (clone FA6–152) that specific-
ally targets the epitopes for TSP-1 and collagen [39–41]
also failed to prevent VM formation in our assays. Taken
together, this data suggests that CD36-expressing VM-
competent cancer cells may utilize CD36 differently to
ECs for the formation of vascular structures; a process
that is yet to be fully elucidated. Transient knockdown
of CD36 in melanoma cells did not influence cell viabil-
ity but did compromise the number of cells that mi-
grated, again suggesting a role for CD36 in cell adhesion.
This supports recent studies wherein CD36 proved im-
portant for the migration and invasion of breast cancer
cells and cervical cancer cells in vitro [30, 47]. More spe-
cifically, these studies show that CD36 can promote the
activation of the MAPK signaling pathway, upregulate
protein expression of Bcl2 and cyclin D1 and engage
with the TGF-β signaling for epithelial to mesenchymal
transition (EMT) by cancer cells [30, 47].
To further elucidate the role for CD36 on cancer cells
to engage with ECM components, adhesion assays were
Fig. 6 CD36 aids selective adhesion by melanoma cells to components of the ECM. Rose Bengal staining of C32 melanoma cells, without and
with siCD36 knockdown (untreated (UNT), siRNA control (si-SCR), and CD36-targeting siRNA (siCD36 A and C)) following 90min exposure to
plates coated with Geltrex, Collagen I, Collagen IV, Laminin or Fibronectin. Data are mean ± SEM from n = 3 experiments. * p < 0.05, **p < 0.01,
one-way ANOVA
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performed on collagen I, collagen IV, laminin and fibro-
nectin, all of which are in high abundance in the ECM
of tumors [48] and all are documented ligands for CD36
[42]. Here we observed that loss of CD36 significantly
reduced the ability of melanoma cells to bind to the lam-
inin substrata while retaining full binding capacity to
collagen I, collagen IV and fibronectin. The retained
binding to collagen is supported by our observations of
the anti-CD36 monoclonal antibody (clone FA6–152
[39–41]) failing to inhibit VM formation by the cancer
cells. Our observation of CD36-knockdown melanoma
cells exhibiting reduced adhesion to laminin concurs
with a study by Ladanyi and colleagues who demon-
strated that ovarian cancer cells utilize CD36 for adhe-
sion to laminin [27]. A potential mechanism by which
this interaction may occur is via a lateral association
with integrins, specifically the laminin binding integrins
α3β1 and α6β1 [49, 50] both of which have been reported
Fig. 7 Integrin-α3 supports melanoma cell adhesion to laminin. (A) Flow cytometric analysis of integrin-α3 expression on C32 melanoma cells
with isotype control (dotted line) and integrin-α3 (solid line). (B) Adhesion of C32 melanoma cells on to laminin coated coverslips for 60 min
prior to staining for integrin-α3 (left panel), paxillin (middle panel) and a nuclear stain (DAPI, colored merged image). Dual stained focal contacts
shown in high magnification insert (bottom right). Isotype control stains shown in the top insert. Scale bar = 10 μm. (C) Adhesion of C32
melanoma cells treated with an anti-integrin-α3 antibody or isotype control onto tissue culture plates coated with 50 μg/ml laminin. Microscopy
images (left) illustrate the density of adherent cells on each well surface. Scale bar = 500 μm. Bar graph (right), quantification of C32 melanoma
cell adhesion to laminin as assessed following treatment with a blocking anti-integrin-α3 antibody or isotype control. Results are normalized to
control (ctl) wells and are mean ± SEM from n = 3 experiments. *p < 0.05, t-test
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to associate with CD36 in human melanoma cells for en-
hanced migration on ECM components [42]. Here we
reveal that like CD36, blocking integrin-α3 on melanoma
cells inhibited the binding of melanoma cells to laminin
in vitro. Taken together, this study leads us to
hypothesize that CD36 expression by melanoma cells
modulates the function of integrins to promote shape
change and migration on ECM components, thereby fa-
cilitating the formation of VM structures (Fig. 8).
Increasing literature demonstrates that overexpression
of CD36 in cell lines of cervical and oral squamous cell
carcinoma significantly increases their metastatic poten-
tial in vivo [29, 30]. In accordance, CD36 neutralizing
antibodies have been successfully used to combat metas-
tasis in mouse models [29]. More specifically, repeated
injections of the anti-CD36 antibody (clone FA6–152)
significantly attenuated the metastasis of oral squamous
cell carcinoma without effect on the primary tumor [29].
Whether these anti-CD36 treated tumors contained
fewer VM structures was not determined.
Our in-silico analysis of the TCGA database supports
our hypothesis that high expression of CD36 correlates
with poor outcome for patients with melanoma.
Whether CD36 could serve as a useful biomarker for
personalized medicine is not known, but with clinical
trials targeting CD36 for patients with metabolic disease
[43, 51], an opportunity to repurpose an anti-CD36 mol-
ecule remains of interest. Notably, caution surrounding
CD36 as a target to treat cancer is unsurprising given
that it is a fatty acid scavenger receptor with a wide
range of ligands. Indeed, lipotoxicity was observed in
tumor bearing mice treated with the CD36-neutralising
antibody [29]. Clearly, while the refinement of CD36-
targeting antibodies requires significant attention, there
is increasing interest in CD36 as a potential prognostic
for patients with colon, ovarian, breast, small cell lung
carcinoma and urinary bladder cancer [29, 43, 44] and
melanoma. This study adds to this interest by identifying
a key role for CD36 in the lateral interactions with
integrin-α3 to promote adhesion to the ECM (particu-
larly laminin) to facilitate VM formation, an emerging
process that contributes significantly to the progression
of cancer (Fig. 8).
Conclusions
The results from this study identify CD36 as a previ-
ously unrecognized regulator of VM by melanoma
cancer cells. The VM process is multifaceted and our
Fig. 8 Schematic concept of CD36 in VM formation and cancer progression. Solid tumor growth is underpinned by angiogenesis and VM. We
hypothesize that CD36 expression by tumor ECs and the cancer cells themselves interacts with integrin-α3 to promote adhesion to the tumor
ECM (particularly laminin) thus facilitating tumor vascularization (i.e. angiogenesis and VM) and cancer progression. Thrombospondin (TSP-1) is a
ligand for CD36 and inhibits EC-lined angiogenesis. By contrast, VM by highly malignant melanoma cells is unperturbed when TSP-1 binds CD36.
This schematic was conceptualized and crafted by CSB using Microsoft PowerPoint
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study suggests that CD36 contributes by co-operating
with adhesion molecules (such as integrin-α3) to en-
gage with components of the tumor microenviron-
ment (such as laminin). Interestingly, our results
suggest that VM differs from angiogenesis in that
TSP-1 does not inhibit VM formation whereas it does
perturb angiogenesis by ECs. This new information
contributes to our understanding that both ECs and
cancer cells form vascular structures within a tumor
mass via processes that are not entirely identical.
These differences will become important as we work
towards specifically targeting tumor vascularization to
best combat cancer progression.
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